newsfilter
← Latest News
PR Newswire·

TC BioPharm Announces Successful Dosing of Final Patient in ACHIEVE Safety Cohort

Phase 2B Clinical Trial Evaluating Omnimmune® in AML Patients EDINBURGH, Scotland, Feb. 7, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP)